One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Long COVID: long-term health outcomes and implications for policy and research
Ziyad Al-Aly, Anupam Agarwal, Nisreen Alwan & Valerie A. LuyckxÂÂ
doi : 10.1038/s41581-022-00652-2
Volume 19 Issue 1, January 2023
Kidney benefits of SLGT2 inhibitors: evidence from clinical trials
Monica WangÂÂ
Spatial metabolic tracing in the kidney � the future is now
Alessandra BolettaÂÂ
The pathogenesis of pre-eclampsia in kidney donors
Giorgina Barbara Piccoli & Oralia Alejandra Orozco-GuillénÂÂ
Advances in CRISPR therapeutics
Michael Chavez, Xinyi Chen, Paul B. Finn & Lei S. QiÂÂ
doi : 10.1038/s41581-022-00636-2
The clustered regularly interspaced short palindromic repeats (CRISPR) renaissance was catalysed by the discovery that RNA-guided prokaryotic CRISPR-associated (Cas) proteins can create targeted double-strand breaks in mammalian genomes.
Trained immunity � basic concepts and contributions to immunopathology
Jordi Ochando 1,2 ✉, Willem J. M. Mulder 3,4 , Joren C. Madsen 5,6 , Mihai G. Netea 7,8 and Raphaël Duivenvoorden
doi : 10.1038/s41581-022-00633-5
Trained immunity is a functional state of the innate immune response and is characterized by long-term epigenetic reprogramming of innate immune cells. This concept originated in the field of infectious diseases � training of innate immune cells, such as monocytes, macrophages and/or natural killer cells, by infection or vaccination enhances immune responses against microbial pathogens after restimulation.
Therapeutic advances in COVID-19
Naoka Murakami, Robert Hayden, Thomas Hills, Hanny Al-Samkari, Jonathan Casey, Lorenzo Del Sorbo, Patrick R. Lawler, Meghan E. Sise & David E. LeafÂÂ
doi : 10.1038/s41581-022-00642-4
Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed millions of lives. Unlike the early days of the pandemic, when management decisions were based on extrapolations from in vitro data, case reports and case series, clinicians are now equipped with an armamentarium of therapies based on high-quality evidence.
Cisplatin nephrotoxicity: new insights and therapeutic implications
Chengyuan Tang, Man J. Livingston, Robert Safirstein & Zheng DongÂÂ
doi : 10.1038/s41581-022-00631-7
Cisplatin is an effective chemotherapeutic agent for various solid tumours, but its use is limited by adverse effects in normal tissues. In particular, cisplatin is nephrotoxic and can cause acute kidney injury and chronic kidney disease.
